Holocene Advisors
STRO icon

Holocene Advisors’s Sutro Biopharma STRO Stock Holding History

Holocene Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-213,287
Closed -$7.4M – 828
2023
Q3 		$7.4M Hold
213,287
– – 0.03% 319
2023
Q2 		$9.92M Hold
213,287
– – 0.04% 256
2023
Q1 		$9.85M Sell
213,287
-18,067
-8% -$1.15M 0.05% 238
2022
Q4 		$18.7M Sell
231,354
-49,166
-18% -$3.42M 0.11% 189
2022
Q3 		$15.6M Hold
280,520
– – 0.1% 197
2022
Q2 		$14.6M Buy
280,520
+97,344
+53% +$5.44M 0.09% 196
2022
Q1 		$15.1M Buy
183,176
+24,818
+16% +$2.36M 0.08% 203
2021
Q4 		$23.6M Sell
158,358
-2,389
-1% -$428K 0.12% 185
2021
Q3 		$30.4M Buy
160,747
+1,059
+0.7% +$201K 0.17% 168
2021
Q2 		$29.7M Buy
159,688
+17,367
+12% +$3.4M 0.17% 160
2021
Q1 		$32.4M Buy
142,321
+35,595
+33% +$8.45M 0.2% 139
2020
Q4 		$23.2M Buy
+106,726
New +$17.7M 0.15% 191

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Holocene Advisors's STRO Position: Q4 2023 in Review

Holocene Advisors sold out of Sutro Biopharma (STRO) in Q4 2023, closing a stake of 213,287 shares — an estimated $7.4M sold.

Holocene Advisors first reported a position in STRO in Q4 2020 and held it in 12 quarters. The position peaked at $32.4M in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q4 2023.

  • Holocene Advisors reported no remaining Sutro Biopharma position as of Q4 2023 after selling out during the quarter.
  • Holocene Advisors sold 213,287 Sutro Biopharma shares in Q4 2023, an estimated $7.4M.
  • Holocene Advisors first reported a position in Sutro Biopharma in Q4 2020 and held it in 12 quarters.
  • Holocene Advisors's Sutro Biopharma position peaked at $32.4M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2023.

Based on Holocene Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.